Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

D. Shanafelt, Tait; V. Wang, Xin; E. Kay, Neil; A. Hanson, Curtis; O’Brien, Susan; C. Barrientos, Jacqueline; F. Jelinek, Diane; Braggio, Esteban; F. Leis, José; C. Zhang, Cong; Coutré, Steven; M. Barr, Paul; F. Cashen, Amanda; R. Mato, Anthony; K. Singh, Avina; P. Mullane, Michael; F. Little, Richard; P. Erba, Harry; M. Stone, Richard; R. Litzow, Mark; S. Tallman, Martin

doi:10.1056/nejmoa1817073

Public

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Published in New England Journal of Medicine • Jul 31, 2019

Authors:

Tait D. Shanafelt

Xin V. Wang

Neil E. Kay

Abstract

BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. METHODS: In a phase 3 trial, we r...

Subject

Ibrutinib

Chemoimmunotherapy

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!